Why Enteric Coating Protects the Stomach in Long-Term Aspirin Use
Aspirin (acetylsalicylic acid) irritates the stomach lining by directly contacting and eroding its protective mucus layer, increasing risks of ulcers, bleeding, and gastritis—issues that worsen with daily, long-term use for heart disease prevention or pain management.[1] Enteric coating encases the tablet in a pH-sensitive polymer that resists breakdown in the acidic stomach (pH 1-3) but dissolves in the neutral small intestine (pH 5-7), releasing the drug downstream and minimizing gastric exposure.[2]
How Does the Coating Actually Work?
The polymer—often cellulose acetate phthalate or methacrylic acid copolymers—stays intact below pH 5, preventing aspirin from dissolving where it causes harm. Once in the intestines, it disintegrates, allowing absorption. This delays onset by 1-2 hours compared to plain aspirin but cuts direct mucosal contact by over 90% in studies.[3][4]
What Happens Without It for Long-Term Users?
Uncoated aspirin raises gastrointestinal bleeding risk 2-4 times higher, with odds escalating after months or years of use (e.g., 1-2% annual bleed rate in low-dose therapy). Symptoms include black stools, anemia, or perforation; elderly users or those on blood thinners face 10-fold higher odds.[5] Buffered versions help mildly but don't match enteric protection.
Are There Drawbacks or Better Alternatives?
Enteric aspirin absorbs slower, potentially reducing peak antiplatelet effects slightly in acute settings, though equivalent for chronic use.[6] Downsides include higher cost and rare coating defects causing dumps. Alternatives: proton pump inhibitors (PPIs) like omeprazole alongside plain aspirin, or coated generics. Clopidogrel or ticagrelor sometimes replace aspirin entirely for high-risk patients.[7]
Who Needs It Most and What Do Guidelines Say?
Cardiac patients on 81mg daily benefit most, per ACC/AHA guidelines recommending enteric or buffered forms to curb GI events.[8] Not essential for short-term use, but crucial beyond 3-6 months.
[1] Lanas A, et al. Lancet 2000;355:1737-40.
[2] DrugBank: Aspirin (DB00945).
[3] Hoftiezer JW, et al. Gut 1980;21:329-33.
[4] FDA Label: Aspirin Enteric-Coated Tablets.
[5] Bhatt DL, et al. NEJM 2010;363:2187-99.
[6] Paterson JR, et al. Br J Clin Pharmacol 2006;62:704-9.
[7] ASGE Guidelines on GI Risk in Antiplatelets.
[8] ACC/AHA 2016 Guideline Update: Antiplatelet Therapy.